Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis
pharmaceutical investing Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA
pharmaceutical investing Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
EnerCom Announces Initial List of Presenting Companies for the 31st Annual Energy Investment Conference to be held August 17-19, 2026, in Denver, Colorado
